These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 23787123)

  • 1. Subcutaneous omacetaxine mepesuccinate in patients with chronic-phase chronic myeloid leukemia previously treated with 2 or more tyrosine kinase inhibitors including imatinib.
    Cortes JE; Nicolini FE; Wetzler M; Lipton JH; Akard L; Craig A; Nanda N; Benichou AC; Leonoudakis J; Khoury HJ; Hochhaus A; Baccarani M; Kantarjian HM
    Clin Lymphoma Myeloma Leuk; 2013 Oct; 13(5):584-91. PubMed ID: 23787123
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic-phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors.
    Cortes J; Digumarti R; Parikh PM; Wetzler M; Lipton JH; Hochhaus A; Craig AR; Benichou AC; Nicolini FE; Kantarjian HM;
    Am J Hematol; 2013 May; 88(5):350-4. PubMed ID: 23468307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Final analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronic- or accelerated-phase chronic myeloid leukemia: Results with 24 months of follow-up.
    Cortes JE; Kantarjian HM; Rea D; Wetzler M; Lipton JH; Akard L; Khoury HJ; Michallet M; Guerci-Bresler A; Chuah C; Hellmann A; Digumarti R; Parikh PM; Legros L; Warzocha K; Baccarani M; Li E; Munteanu M; Nicolini FE
    Cancer; 2015 May; 121(10):1637-44. PubMed ID: 25586015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation.
    Cortes J; Lipton JH; Rea D; Digumarti R; Chuah C; Nanda N; Benichou AC; Craig AR; Michallet M; Nicolini FE; Kantarjian H;
    Blood; 2012 Sep; 120(13):2573-80. PubMed ID: 22896000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. U.S. Food and Drug Administration approval summary: omacetaxine mepesuccinate as treatment for chronic myeloid leukemia.
    Alvandi F; Kwitkowski VE; Ko CW; Rothmann MD; Ricci S; Saber H; Ghosh D; Brown J; Pfeiler E; Chikhale E; Grillo J; Bullock J; Kane R; Kaminskas E; Farrell AT; Pazdur R
    Oncologist; 2014 Jan; 19(1):94-9. PubMed ID: 24309980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Omacetaxine for treatment-resistant or treatment-intolerant adult chronic myeloid leukemia.
    Chung C
    Am J Health Syst Pharm; 2014 Feb; 71(4):279-88. PubMed ID: 24481153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence and management of myelosuppression in patients with chronic- and accelerated-phase chronic myeloid leukemia treated with omacetaxine mepesuccinate.
    Akard L; Kantarjian HM; Nicolini FE; Wetzler M; Lipton JH; Baccarani M; Jean Khoury H; Kurtin S; Li E; Munteanu M; Cortes J
    Leuk Lymphoma; 2016; 57(3):654-65. PubMed ID: 26436949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Omacetaxine mepesuccinate in patients with advanced chronic myeloid leukemia with resistance or intolerance to tyrosine kinase inhibitors.
    Khoury HJ; Cortes J; Baccarani M; Wetzler M; Masszi T; Digumarti R; Craig A; Benichou AC; Akard L
    Leuk Lymphoma; 2015 Jan; 56(1):120-7. PubMed ID: 24650054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic study of omacetaxine mepesuccinate administered subcutaneously to patients with advanced solid and hematologic tumors.
    Nemunaitis J; Mita A; Stephenson J; Mita MM; Sarantopoulos J; Padmanabhan-Iyer S; Nanda N; Gleich L; Benichou AC; Craig A
    Cancer Chemother Pharmacol; 2013 Jan; 71(1):35-41. PubMed ID: 23053254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Omacetaxine mepesuccinate--a semisynthetic formulation of the natural antitumoral alkaloid homoharringtonine, for chronic myelocytic leukemia and other myeloid malignancies.
    Quintás-Cardama A; Cortes J
    IDrugs; 2008 May; 11(5):356-72. PubMed ID: 18465678
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia.
    Shah NP; Kantarjian HM; Kim DW; Réa D; Dorlhiac-Llacer PE; Milone JH; Vela-Ojeda J; Silver RT; Khoury HJ; Charbonnier A; Khoroshko N; Paquette RL; Deininger M; Collins RH; Otero I; Hughes T; Bleickardt E; Strauss L; Francis S; Hochhaus A
    J Clin Oncol; 2008 Jul; 26(19):3204-12. PubMed ID: 18541900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure.
    Khoury HJ; Cortes JE; Kantarjian HM; Gambacorti-Passerini C; Baccarani M; Kim DW; Zaritskey A; Countouriotis A; Besson N; Leip E; Kelly V; Brümmendorf TH
    Blood; 2012 Apr; 119(15):3403-12. PubMed ID: 22371878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.
    Hochhaus A; Baccarani M; Deininger M; Apperley JF; Lipton JH; Goldberg SL; Corm S; Shah NP; Cervantes F; Silver RT; Niederwieser D; Stone RM; Dombret H; Larson RA; Roy L; Hughes T; Müller MC; Ezzeddine R; Countouriotis AM; Kantarjian HM
    Leukemia; 2008 Jun; 22(6):1200-6. PubMed ID: 18401416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Omacetaxine mepesuccinate prevents cytokine-dependent resistance to nilotinib in vitro: potential role of the common β-subunit c of cytokine receptors.
    Klag T; Härtel N; Erben P; Schwaab J; Schnetzke U; Schenk T; Hochhaus A; La Rosée P
    Leukemia; 2012 Jun; 26(6):1321-8. PubMed ID: 22289991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative efficacy and tolerability of front-line treatments for newly diagnosed chronic-phase chronic myeloid leukemia: an update network meta-analysis.
    Tang L; Zhang H; Peng YZ; Li CG; Jiang HW; Xu M; Mei H; Hu Y
    BMC Cancer; 2019 Aug; 19(1):849. PubMed ID: 31462241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy.
    Giles FJ; Abruzzese E; Rosti G; Kim DW; Bhatia R; Bosly A; Goldberg S; Kam GL; Jagasia M; Mendrek W; Fischer T; Facon T; Dünzinger U; Marin D; Mueller MC; Shou Y; Gallagher NJ; Larson RA; Mahon FX; Baccarani M; Cortes J; Kantarjian HM
    Leukemia; 2010 Jul; 24(7):1299-301. PubMed ID: 20520639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Omacetaxine Mepesuccinate for Chronic Myeloid Leukemia.
    Rosshandler Y; Shen AQ; Cortes J; Khoury HJ
    Expert Rev Hematol; 2016 May; 9(5):419-24. PubMed ID: 26853281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia.
    O'Brien S; Talpaz M; Cortes J; Shan J; Giles FJ; Faderl S; Thomas D; Garcia-Manero G; Mallard S; Beth M; Koller C; Kornblau S; Andreeff M; Murgo A; Keating M; Kantarjian HM
    Cancer; 2002 Apr; 94(7):2024-32. PubMed ID: 11932905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subcutaneous omacetaxine mepesuccinate in patients with chronic myeloid leukemia in tyrosine kinase inhibitor-resistant patients: review and perspectives.
    Heiblig M; Sobh M; Nicolini FE
    Leuk Res; 2014 Oct; 38(10):1145-53. PubMed ID: 24906663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R).
    Kantarjian H; Pasquini R; Lévy V; Jootar S; Holowiecki J; Hamerschlak N; Hughes T; Bleickardt E; Dejardin D; Cortes J; Shah NP
    Cancer; 2009 Sep; 115(18):4136-47. PubMed ID: 19536906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.